AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020

Rhea-AI Summary

Applied Genetic Technologies Corporation (AGTC) will report its financial results for the fiscal quarter ending March 31, 2020, on May 13, 2020, before market opening. A conference call is scheduled for 8:00 AM ET on the same day to review the results and provide updates. AGTC is focused on gene therapies for rare diseases, with ongoing clinical trials in ophthalmology including conditions like X-linked retinitis pigmentosa and achromatopsia. The company also has preclinical programs targeting other serious diseases.

GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2020 before the market opens on Wednesday, May 13, 2020. AGTC management will host a conference call beginning at 8:00 AM Eastern Time that day to review results and provide a corporate update.

To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About AGTC

AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trial programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3) as well as an optogenetics program that is being developed in collaboration with Bionic Sight. In addition to its clinical trials, AGTC has preclinical programs in otology and adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), which are diseases of the central nervous system (CNS), and other ophthalmology indications including Stargardts and dry age-related macular degeneration (dry AMD). The otology program is being developed in collaboration with Otonomy. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728  
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

When will AGTC report its financial results?

AGTC will report its financial results for the fiscal quarter ended March 31, 2020, on May 13, 2020.

What will AGTC discuss during the conference call on May 13, 2020?

During the conference call on May 13, AGTC will review its financial results and provide a corporate update.

What are the main focuses of AGTC's clinical trials?

AGTC's clinical trials focus on gene therapies for rare diseases, particularly in ophthalmology for conditions like X-linked retinitis pigmentosa and achromatopsia.